Alzheimer Disease Imaging in the Era of Anti-Amyloid Treatment

IF 0.4 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Applied Radiology Pub Date : 2023-09-01 DOI:10.37549/ar2918
Suzie Bash, Lawrence N. Tanenbaum
{"title":"Alzheimer Disease Imaging in the Era of Anti-Amyloid Treatment","authors":"Suzie Bash, Lawrence N. Tanenbaum","doi":"10.37549/ar2918","DOIUrl":null,"url":null,"abstract":"The landscape of diagnostic evaluation and treatment of Alzheimer disease (AD) is rapidly changing. While there is still no cure for AD, recent developments are bringing increased hope to the millions of Americans suffering from this progressively debilitating condition. Here we offer an overview of recent regulatory, treatment, and imaging developments that promise to significantly impact AD patients, their families, their physicians, and neuroimaging specialists. An estimated 6.7 million Americans suffer from AD, which doubles in prevalence every five years after the age of 65.1,2 One in three seniors will die of dementia.1 Since 2000, death from heart disease has decreased by 7%, but death from AD has increased by 145%.1 Conventional and quantitative brain MRI, as well as fluorodeoxyglucose (FDG), amyloid, and tau PET are utilized in the evaluation and clinical care pathway for dementia patients (Figures 1-4). With the recent emergence of disease-modifying therapies (DMT) for AD, neuroradiologists will play a critical role in the detection and characterization of treatment-related complications.","PeriodicalId":44386,"journal":{"name":"Applied Radiology","volume":"11 1","pages":"0"},"PeriodicalIF":0.4000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Radiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37549/ar2918","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

The landscape of diagnostic evaluation and treatment of Alzheimer disease (AD) is rapidly changing. While there is still no cure for AD, recent developments are bringing increased hope to the millions of Americans suffering from this progressively debilitating condition. Here we offer an overview of recent regulatory, treatment, and imaging developments that promise to significantly impact AD patients, their families, their physicians, and neuroimaging specialists. An estimated 6.7 million Americans suffer from AD, which doubles in prevalence every five years after the age of 65.1,2 One in three seniors will die of dementia.1 Since 2000, death from heart disease has decreased by 7%, but death from AD has increased by 145%.1 Conventional and quantitative brain MRI, as well as fluorodeoxyglucose (FDG), amyloid, and tau PET are utilized in the evaluation and clinical care pathway for dementia patients (Figures 1-4). With the recent emergence of disease-modifying therapies (DMT) for AD, neuroradiologists will play a critical role in the detection and characterization of treatment-related complications.
抗淀粉样蛋白治疗时代的阿尔茨海默病成像
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Applied Radiology
Applied Radiology RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
CiteScore
0.20
自引率
0.00%
发文量
64
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信